Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
122 hedge funds and large institutions have $402M invested in Achillion Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 43 increasing their positions, 32 reducing their positions, and 13 closing their positions.
127% more call options, than puts
Call options by funds: $1.94M | Put options by funds: $854K
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
37% more capital invested
Capital invested by funds: $294M → $402M (+$108M)
34% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 32
7% more funds holding
Funds holding: 114 → 122 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$7.71M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$3.37M |
| 3 |
Renaissance Technologies
New York
|
+$3.26M |
| 4 |
PVI
Pura Vida Investments
New York
|
+$2.18M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$4.52M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.16M |
| 3 |
Millennium Management
New York
|
-$4.01M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.11M |
| 5 |
Man Group
London,
United Kingdom
|
-$1.86M |
ACHN Hedge Fund Activity: Q3 2019 in Review
122 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q3 2019, worth a combined $402M — up 37% from $294M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ACHN positions and 13 closed out — a net gain of 8 holders — while 43 added to existing stakes and 32 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $7.71M. The largest seller was State Street, cutting an estimated $4.52M.
- 122 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q3 2019, up from 114 in Q2 2019.
- Funds reported $402M of Achillion Pharmaceuticals stock for Q3 2019, up 37% quarter-over-quarter.
- 21 funds opened new Achillion Pharmaceuticals positions in Q3 2019 and 13 closed out, a net change of +8 holders.
- The largest Achillion Pharmaceuticals buyer in Q3 2019 was Boxer Capital, an estimated $7.71M added.
- The largest Achillion Pharmaceuticals seller in Q3 2019 was State Street, an estimated $4.52M sold.
Based on aggregated 13F filings for Q3 2019.